ClinicalTrials.gg
Status unknownNCT03529526Updated May 22, 2018

Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of KN046 in Advanced Solid Tumors, sponsored by Alphamab (Australia) Co Pty Ltd.. Status unknown at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-22.

Sponsored by Alphamab (Australia) Co Pty Ltd. (part of Alphamab Oncology) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multicenter, dose-escalation phase I study to assess the safety, tolerability and preliminary efficacy of KN046 in participants with all advanced solid tumors who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) or a biological effective dose (BED), to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of KN046 as a single agent in adult participants with advanced solid tumors

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Alphamab (Australia) Co Pty Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must sign the form prior to the conduct of any study related procedures that are required during the screening period and are not considered part of standard of care.
  2. Subjects must have histologic or cytologic confirmed Advanced solid tumors.
  3. (ECOG) performance status of 0 or 1.
  4. Adequate organ function within 3 weeks prior to initial treatment.
  5. Ability to comply with treatment, procedures and PK sample collection and the required study follow-up procedures.
  6. Female patients and males with partners of should be using highly effective measures (failure rate of less than 1% per year). Contraception should be continued for a period of 24 weeks after dosing has been completed.
  7. Female patients must have a negative serum or urine pregnancy test
  8. Female patients must not be breastfeeding.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with or are excluded.
  2. Concurrent enrollment in another clinical study, unless in a follow-up period or the study is an observational or non-interventional study.
  3. Any kind of immunotherapy within 6 weeks of the first dose of study treatment.
  4. Prior systemic cytotoxic chemotherapy, other anticancer drugs or growth factor within 28 days of the first dose of study treatment, or any agents within 5 half-lives of the product.
  5. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the 1st dose of study treatment, or have an anticipated need for major surgery during the study.
  6. Palliative radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the 1st dose of study treatment.
  7. Prior treatment or with sequential monotherapy with and anti-PD-1/PD-L agents.
  8. Patients who have received monotherapy with PD-L1 / PD-1, CTLA4 or other antibodies and had intolerable toxicity or required to manage toxicity.
  9. History of or inflammatory disorders.
  10. A current or prior use of medication within 14 days of the 1st dose of study treatment.
  11. Suspected latent tuberculosis infection, confirmed by Mantoux test and a chest x-ray.
  12. Any unresolved toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events) Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
  13. Any factors that increase the risk of ( interval measured from the onset of the QRS complex to the end of the T wave) interval corrected for heart rate (QTc) prolongation or risk of arrhythmic events (e.g., heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age) or mean QTc>470 msec.
  14. Positive blood screen for surface antigen (HBsAg), antibody (HCV Ab), or 1/2 antibody (HIV 1/2 Ab).
  15. History of severe allergic reactions to any unknown allergens or to parenteral administered recombinant protein product.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    KN046

    Drug: KN046

Interventions

  • DrugKN046

    The modified phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg.

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicity (DLT)

    An DLT is defined as a ≥Grade 3 drug-related adverse event occurring within the first cycle (28 days) of dosing (excluding tumor flare causing local pain at sites of known or suspected tumor, localized rash, or a transient ≤Grade 3 infusion reaction) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: During the first cycle (4 weeks) of treatment.

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    An AE is defined as any untoward medical occurrence in a participant administered KN046 and/or pharmaceutical product(s) temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From the time of informed consent signed through 90 days after the last dose of KN046,up to 2 years.

  2. Objective response rate (ORR)

    The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.

    Time frame: From first dose of KN046 through 90 days after last dose of KN046, up to 2 years.

  3. Duration of response (DoR)

    Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: up to 2 years.

  4. Progression-free survival (PFS)

    Progression-free survival is defined as the time from the start of treatment with KN046 until the first documentation of disease progression or death due to any cause, whichever occurs first.

    Time frame: From first dose of KN046 through 90 days after last dose of KN046, up to 2 years.

  5. Clinical benefit rate (CBR)

    Clinical benefit rate is defined as the percentage of patients who have achieved complete response (CR), partial response (PR) and stable disease (SD) to KN046 intervention.

    Time frame: From first dose of KN046 through 90 days after last dose of KN046, up to 2 years.

  6. Area under the curve (AUC) of KN046

    The endpoints for assessment of PK of KN046 include serum concentrations of KN046 at different timepoints after KN046 administration.

    Time frame: From first dose of KN046 through 90 days after last dose of KN046, up to 9 months.

  7. Maximum observed concentration (Cmax) of KN046

    The endpoints for assessment of PK of KN046 include serum concentrations of KN046 at different timepoints after KN046 administration.

    Time frame: From first dose of KN046 through 90 days after last dose of KN046, up to 9 months.

  8. Minimum observed plasma concentration (Ctrough) of KN046 at steady state

    The endpoints for assessment of PK of KN046 include serum concentrations of KN046 at different timepoints after KN046 administration.

    Time frame: From first dose of KN046 through 90 days after last dose of KN046, up to 9 months.

  9. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of KN046 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).

    Time frame: Assessed before KN046 infusion in Cycle 1, 2, 3, 4, 5, 6 and at the mandatory Safety Follow-up Visit, maxium up to 2 years.

  10. Number of subjects who develop detectable neutralizing ADA (NADA)

    The neutralizing ADA will be assessed by summarizing the number of subjects who develop detectable neutralizing ADA .

    Time frame: Assessed before KN046 infusion in Cycle 1, 2, 3, 4, 5, 6 and at the mandatory Safety Follow-up Visit, maxium up to 2 years.

07

Study locations

1 of 1 sites recruiting
  • ICON Cancer Care
    Southport, Queensland 4125, Australia
    Recruiting
    • Jermaine Coward, A/Prof · Contactjim.coward@gmail.com · +61-07-3737-4500
    • Vinod Ganju · Principal investigator
    • Gary Richardson · Principal investigator
    • Craig Underhill · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2018; primary completion for Oct 2019, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2018
First posted
May 18, 2018
StartEst.
May 21, 2018
Primary completionEst.
Oct 30, 2019
CompletionEst.
Mar 30, 2020
Last update
May 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03529526
Responsible party
Sponsor
First posted
May 18, 2018
Start date
May 21, 2018 (estimated)
Primary completion
Oct 30, 2019 (estimated)
Completion
Mar 30, 2020 (estimated)
Last update
May 22, 2018

Study contacts

Jermaine Coward, A/Prof
Contact
jim.coward@gmail.com
+61-07-3737-4500

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Erfonrilimab

Start the discussion